Prenatal maternal infection and maternal iron deficiency during pregnancy are 2 early environmental insults associated with increased risk for schizophrenia in offspring. Substantial evidence suggests that abnormalities in inhibitory γ-aminobutyric acid (GABA) interneuron function, especially in the parvalbumin subtype of GABA interneuron, both developmentally and in adulthood, may contribute mechanistically to cognitive deficits and psychotic symptoms in schizophrenia. This study used a rat model to test whether prenatal immune activation with lipopolysaccharide (LPS; at gestation days, GD, 15 and 16) or maternal iron deficiency (from GD2 to postnatal day P7) or the combination of both insults alters major subtypes of GABAergic interneurons (parvalbumin, somatostatin, cholecystokinin) in brain regions relevant to schizophrenia (medial and dorsolateral prefrontal cortex [PFC], hippocampal CA1 and dentate gyrus, ventral subiculum) in offspring at P14 or P28. Prenatal LPS treatment significantly increased the density of parvalbumin-immunoreactive neurons at P14 in the medial PFC, dorsolateral PFC, and ventral subiculum of offspring born from iron-sufficient but not iron-deficient dams. Prenatal LPS also increased cholecystokinin neuron density in the medial PFC at P28, under both iron-sufficient and iron-deficient conditions. We observed a large increase in parvalbumin neuron density from P14 to P28 in the medial PFC and subiculum across all birth groups, that was not observed in other brain regions, and significant decreases in somatostatin neuron density from P14 to P28 in all brain regions examined across all birth groups, indicating differential developmental trajectories for parvalbumin and somatostatin neurons in various brain regions during this early postnatal period. Thus, it appears that the medial PFC and ventral subiculum, brain regions involved in circuitry modulating ventral tegmental dopamine and nucleus accumbens activities, may be regions vulnerable to effects of prenatal LPS on specific subpopulations of interneurons. It is known that the timing of maturation and expansion of parvalbumin neurons in early development provides threshold levels of inhibition that trigger critical periods for cortical plasticity, leading to long-term circuit consolidation. Thus, our finding of increased parvalbumin neuron density at early developmental times might suggest a mechanism by which an acute prenatal insult like LPS exposure could produce long-term changes in prefrontal cortical or subicular function.

Keywords:
Animal model, γ-Aminobutyric acid, Interneurons, Lipopolysaccharide, Prenatal infection, Schizophrenia
1.
Schmidt MJ, Mirnics K: Neurodevelopment, GABA system dysfunction, and schizophrenia. Neuropsychopharmacology 2015;40:190-206.
2.
Volk DW, Lewis DA: Early developmental disturbances of cortical inhibitory neurons: contribution to cognitive deficits in schizophrenia. Schizophr Bull 2014;40:952-957.
3.
Brisch R, Bielau H, Saniotis A, Wolf R, Bogerts B, Krell D, Steiner J, Braun K, Krzyżanowska M, Krzyżanowski M, Jankowski Z, Kaliszan M, Bernstein HG, Gos T: Calretinin and parvalbumin in schizophrenia and affective disorders: a mini-review, a perspective on the evolutionary role of calretinin in schizophrenia, and a preliminary post-mortem study of calretinin in the septal nuclei. Front Cell Neurosci 2015;9:393.
4.
Hashimoto T, Volk DW, Eggan SM, Mirnics K, Pierri JN, Sun Z, Sampson AR, Lewis DA: Gene expression deficits in a subclass of GABA neurons in the prefrontal cortex of subjects with schizophrenia. J Neurosci 2003;23:6315-6326.
5.
Fung SJ, Fillman SG, Webster MJ, Shannon Weickert C: Schizophrenia and bipolar disorder show both common and distinct changes in cortical interneuron markers. Schizophr Res 2014;155:26-30.
6.
Joshi D, Fung SJ, Rothwell A, Weickert CS: Higher gamma-aminobutyric acid neuron density in the white matter of orbital frontal cortex in schizophrenia. Biol Psychiatry 2012;72:725-733.
7.
Volk DW, Edelson JR, Lewis DA: Altered expression of developmental regulators of parvalbumin and somatostatin neurons in the prefrontal cortex in schizophrenia. Schizophr Res 2016;177:3-9.
8.
Gonzalez-Burgos G, Cho RY, Lewis DA: Alterations in cortical network oscillations and parvalbumin neurons in schizophrenia. Biol Psychiatry 2015;77:1031-1040.
9.
Lee SY, Földy C, Szabadics J, Soltesz I: Cell-type-specific CCK2 receptor signaling underlies the cholecystokinin-mediated selective excitation of hippocampal parvalbumin-positive fast-spiking basket cells. J Neurosci 2011;31:10993-11002.
10.
Khandaker GM, Zimbron J, Lewis G, Jones PB: Prenatal maternal infection, neurodevelopment and adult schizophrenia: a systematic review of population-based studies. Psychol Med 2013;43:239-257.
11.
Sørensen HJ, Nielsen PR, Pedersen CB, Mortensen PB: Association between prepartum maternal iron deficiency and offspring risk of schizophrenia: population-based cohort study with linkage of Danish national registers. Schizophr Bull 2011;37:982-987.
12.
Insel BJ, Schaefer CA, McKeague IW, Susser ES, Brown AS: Maternal iron deficiency and the risk of schizophrenia in offspring. Arch Gen Psychiatry 2008;65:1136-1144.
13.
Velu PP, Gravett CA, Roberts TK, Wagner TA, Zhang JS, Rubens CE, Gravett MG, Campbell H, Rudan I: Epidemiology and aetiology of maternal bacterial and viral infections in low- and middle-income countries. J Glob Health 2011;1:171-188.
14.
Milman N: Anemia - still a major health problem in many parts of the world! Ann Hematol 2011;90:369-377.
15.
McLean E, Cogswell M, Egli I, Wojdyla D, de Benoist B: Worldwide prevalence of anaemia, WHO Vitamin and Mineral Nutrition Information System, 1993-2005. Public Health Nutr 2009;12:444-454.
16.
Nouel D, Burt M, Zhang Y, Harvey L, Boksa P: Prenatal exposure to bacterial endotoxin reduces the number of GAD67- and reelin-immunoreactive neurons in the hippocampus of rat offspring. Eur Neuropsychopharmacol 2012;22:300-307.
17.
Wischhof L, Irrsack E, Osorio C, Koch M: Prenatal LPS-exposure - a neurodevelopmental rat model of schizophrenia - differentially affects cognitive functions, myelination and parvalbumin expression in male and female offspring. Prog Neuropsychopharmacol Biol Psychiatry 2015;57:17-30.
18.
Baharnoori M, Bhardwaj SK, Srivastava LK: Effect of maternal lipopolysaccharide administration on the development of dopaminergic receptors and transporter in the rat. PLoS One 2013;8:e54439.
19.
Basta-Kaim A, Fijał K, Ślusarczyk J, Trojan E, Głombik K, Budziszewska B, Leśkiewicz M, Regulska M, Kubera M, Lasoń W, Wędzony K: Prenatal administration of lipopolysaccharide induces sex-dependent changes in glutamic acid decarboxylase and parvalbumin in the adult rat brain. Neuroscience 2015;287:78-92.
20.
Callahan LS, Thibert KA, Wobken JD, Georgieff MK: Early-life iron deficiency anemia alters the development and long-term expression of parvalbumin and perineuronal nets in the rat hippocampus. Dev Neurosci 2013;35:427-436.
21.
Harvey L, Boksa P: Do prenatal immune activation and maternal iron deficiency interact to affect neurodevelopment and early behavior in rat offspring? Brain Behav Immun 2014;35:144-154.
22.
Harvey L, Boksa P: Additive effects of maternal iron deficiency and prenatal immune activation on adult behaviors in rat offspring. Brain Behav Immun 2014;40:27-37.
23.
Rao R, de Ungria M, Sullivan D, Wu P, Wobken JD, Nelson CA, Georgieff MK: Perinatal brain iron deficiency increases the vulnerability of rat hippocampus to hypoxic ischemic insult. J Nutr 1999;129:199-206.
24.
De Deungria M, Rao R, Wobken JD, Luciana M, Nelson CA, Georgieff MK: Perinatal iron deficiency decreases cytochrome c oxidase (CytOx) activity in selected regions of neonatal rat brain. Pediatr Res 2000;48:169-176.
25.
Unger EL, Hurst AR, Georgieff MK, Schallert T, Rao R, Connor JR, Kaciroti N, Lozoff B, Felt B: Behavior and monoamine deficits in prenatal and perinatal iron deficiency are not corrected by early postnatal moderate-iron or high-iron diets in rats. J Nutr 2012;142:2040-2049.
26.
Paxinos G, Watson C: The Rat Brain in Stereotaxic Coordinates, ed 7. San Diego, Academic Press, 2013.
27.
Meyer-Lindenberg A: From maps to mechanisms through neuroimaging of schizophrenia. Nature 2010;468:194-202.
28.
Grace AA: Dopamine system dysregulation by the hippocampus: implications for the pathophysiology and treatment of schizophrenia. Neuropharmacology 2012;62:1342-1348.
29.
Benes FM, Lange N: Two-dimensional versus three-dimensional cell counting: a practical perspective. Trends Neurosci 2001;24:11-17.
30.
Von Bartheld C: Counting particles in tissue sections: choices of methods and importance of calibration to minimize biases. Histol Histopathol 2002;17:639-648.
31.
Díaz-Cintra S, González-Maciel A, Morales MA, Aguilar A, Cintra L, Prado-Alcalá RA: Protein malnutrition differentially alters the number of glutamic acid decarboxylase-67 interneurons in dentate gyrus and CA1-3 subfields of the dorsal hippocampus. Exp Neurol 2007;208:47-53.
32.
Lema Tomé CM, Miller R, Bauer C, Nottingham C, Smith C, Blackstone K, Brown L, Bryan R, Leigh A, Brady M, Busch J, Turner CP: Decline in age-dependent, MK801-induced injury coincides with developmental switch in parvalbumin expression: cingulate and retrosplenial cortex. Dev Psychobiol 2007;49:606-618.
33.
Osterop SF, Virtanen MA, Loepke JR, Joseph B, Loepke AW, Vutskits L: Developmental stage-dependent impact of midazolam on calbindin, calretinin and parvalbumin expression in the immature rat medial prefrontal cortex during the brain growth spurt. Int J Dev Neurosci 2015;45:19-28.
34.
Ouellet L, de Villers-Sidani E: Trajectory of the main GABAergic interneuron populations from early development to old age in the rat primary auditory cortex. Front Neuroanat 2014;8:40.
35.
Lehmann K, Steinecke A, Bolz J: GABA through the ages: regulation of cortical function and plasticity by inhibitory interneurons. Neural Plast 2012;2012:892784.
36.
Di Cristo G, Chattopadhyaya B, Kuhlman SJ, Fu Y, Bélanger MC, Wu CZ, Rutishauser U, Maffei L, Huang ZJ: Activity-dependent PSA expression regulates inhibitory maturation and onset of critical period plasticity. Nat Neurosci 2007;10:1569-1577.
37.
Patton MH, Bizup BT, Grace AA: The infralimbic cortex bidirectionally modulates mesolimbic dopamine neuron activity via distinct neural pathways. J Neurosci 2013;33:16865-16873.
38.
Belujon P, Grace AA: Critical role of the prefrontal cortex in the regulation of hippocampus-accumbens information flow. J Neurosci 2008;28:9797-9805.
39.
Valenti O, Lodge DJ, Grace AA: Aversive stimuli alter ventral tegmental area dopamine neuron activity via a common action in the ventral hippocampus. J Neurosci 2011;3:4280-4289.
40.
Gill KM, Grace AA: Differential effects of acute and repeated stress on hippocampus and amygdala inputs to the nucleus accumbens shell. Int J Neuropsychopharmacol 2013;16:2013-2025.
41.
Lisman JE, Coyle JT, Green RW, Javitt DC, Benes FM, Heckers S, Grace AA: Circuit-based framework for understanding neurotransmitter and risk gene interactions in schizophrenia. Trends Neurosci 2008;31:234-242.
42.
Piontkewitz Y, Bernstein HG, Dobrowolny H, Bogerts B, Weiner I, Keilhoff G: Effects of risperidone treatment in adolescence on hippocampal neurogenesis, parvalbumin expression, and vascularization following prenatal immune activation in rats. Brain Behav Immun 2012;26:353-363.
43.
Meyer U, Nyffeler M, Yee BK, Knuesel I, Feldon J: Adult brain and behavioral pathological markers of prenatal immune challenge during early/middle and late fetal development in mice. Brain Behav Immun 2008;22:469-486.
44.
Zhang Z, van Praag H: Maternal immune activation differentially impacts mature and adult-born hippocampal neurons in male mice. Brain Behav Immun 2015;45:60-70.
45.
Dickerson DD, Overeem KA, Wolff AR, Williams JM, Abraham WC, Bilkey DK: Association of aberrant neural synchrony and altered GAD67 expression following exposure to maternal immune activation, a risk factor for schizophrenia. Transl Psychiatry 2014;4:e418.
46.
Boksa P: Effects of prenatal infection on brain development and behavior: a review of findings from animal models. Brain Behav Immun 2010;24:881-897.
47.
Miyoshi G, Butt SJ, Takebayashi H, Fishell G: Physiologically distinct temporal cohorts of cortical interneurons arise from telencephalic Olig2-expressing precursors. J Neurosci 2007;27:7786-7798.
48.
Wonders CP, Taylor L, Welagen J, Mbata IC, Xiang JZ, Anderson SA: A spatial bias for the origins of interneuron subgroups within the medial ganglionic eminence. Dev Biol 2008;314:127-136.
49.
Inan M, Welagen J, Anderson SA: Spatial and temporal bias in the mitotic origins of somatostatin- and parvalbumin-expressing interneuron subgroups and the chandelier subtype in the medial ganglionic eminence. Cereb Cortex 2012;22:820-827.
50.
Marsicano G, Lutz B: Expression of the cannabinoid receptor CB1 in distinct neuronal subpopulations in the adult mouse forebrain. Eur J Neurosci 1999;11:4213-4225.
51.
Siegel RA, Düker EM, Fuchs E, Pahnke U, Wuttke W: Responsiveness of mesolimbic, mesocortical, septal and hippocampal cholecystokinin and substance P neuronal systems to stress, in the male rat. Neurochem Int 1984;6:783-789.
52.
Vialou V, Bagot RC, Cahill ME, Ferguson D, Robison AJ, Dietz DM, Fallon B, Mazei-Robison M, Ku SM, Harrigan E, Winstanley CA, Joshi T, Feng J, Berton O, Nestler EJ: Prefrontal cortical circuit for depression- and anxiety-related behaviors mediated by cholecystokinin: role of ΔFosB. J Neurosci 2014;34:3878-3887.
53.
Seillier A, Martinez AA, Giuffrida A: Phencyclidine-induced social withdrawal results from deficient stimulation of cannabinoid CB₁ receptors: implications for schizophrenia. Neuropsychopharmacology 2013;38:1816-1824.
54.
Akdeniz C, Tost H, Meyer-Lindenberg A: The neurobiology of social environmental risk for schizophrenia: an evolving research field. Soc Psychiatry Psychiatr Epidemiol 2014;49:507-517.
55.
Radhakrishnan R, Wilkinson ST, D'Souza DC: Gone to pot - a review of the association between cannabis and psychosis. Front Psychiatry 2014;5:54.
56.
Sultan KT, Brown KN, Shi SH: Production and organization of neocortical interneurons. Front Cell Neurosci 2013;7:221.
57.
Jinno S, Kosaka T: Cellular architecture of the mouse hippocampus: a quantitative aspect of chemically defined GABAergic neurons with stereology. Neurosci Res 2006;56:229-245.
58.
Dallman PR: Biochemical basis for the manifestations of iron deficiency. Annu Rev Nutr 1986;6:13-40.
59.
Georgieff MK: Long-term brain and behavioral consequences of early iron deficiency. Nutr Rev 2011;69(suppl 1):S43-S48.
60.
Akakin D, Martinez-Diaz H, Chen HX, Roper SN: Reduced densities of parvalbumin- and somatostatin-expressing interneurons in experimental cortical dysplasia and heterotopia in early postnatal development. Epilepsy Res 2013;104:226-233.
61.
Papadopoulos GC, Cavanagh ME, Antonopoulos J, Michaloudi H, Parnavelas JG: Postnatal development of somatostatin-containing neurons in the visual cortex of normal and dark-reared rats. Exp Brain Res 1993;92:473-478.
62.
Naus CC, Morrison JH, Bloom FE: Development of somatostatin-containing neurons and fibers in the rat hippocampus. Brain Res 1988;468:113-121.
63.
Tuncdemir SN, Wamsley B, Stam FJ, Osakada F, Goulding M, Callaway EM, Rudy B, Fishell G: Early somatostatin interneuron connectivity mediates the maturation of deep layer cortical circuits. Neuron 2016;89:521-535.
© 2017 S. Karger AG, Basel
2017
Copyright / Drug Dosage / Disclaimer
Copyright: All rights reserved. No part of this publication may be translated into other languages, reproduced or utilized in any form or by any means, electronic or mechanical, including photocopying, recording, microcopying, or by any information storage and retrieval system, without permission in writing from the publisher.
Drug Dosage: The authors and the publisher have exerted every effort to ensure that drug selection and dosage set forth in this text are in accord with current recommendations and practice at the time of publication. However, in view of ongoing research, changes in government regulations, and the constant flow of information relating to drug therapy and drug reactions, the reader is urged to check the package insert for each drug for any changes in indications and dosage and for added warnings and precautions. This is particularly important when the recommended agent is a new and/or infrequently employed drug.
Disclaimer: The statements, opinions and data contained in this publication are solely those of the individual authors and contributors and not of the publishers and the editor(s). The appearance of advertisements or/and product references in the publication is not a warranty, endorsement, or approval of the products or services advertised or of their effectiveness, quality or safety. The publisher and the editor(s) disclaim responsibility for any injury to persons or property resulting from any ideas, methods, instructions or products referred to in the content or advertisements.
You do not currently have access to this content.